Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor + Aspirin vs Aspirin in CABG Patients
NCT05997693Phase 3Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised trial of ticagrelor in coronary artery disease (CAD) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Hierarchical composite of time to death, stroke, myocardial infarction, repeat revascularization and any graft failure at 1 year. Started Aug 2024; status: recruiting.
02
Drugs
ticagrelor
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT05997693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05997693.